View Older Stories View More Recent Stories

Nov 19, 2021 08:03AM Advaxis (ADXS) urges stockholders to carefully evaluate the potential outcomes of the vote on the proposed merger with Biosight
Nov 19, 2021 08:00AM Advaxis, Inc. Issues Letter to Stockholders
Nov 18, 2021 08:00AM Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Advaxis Stockholders Vote “FOR” Proposed Merger with Biosight
Nov 11, 2021 08:00AM Biosight Encourages Advaxis Stockholders to Vote “FOR” Proposed Merger
Nov 4, 2021 08:00AM Advaxis Issues Letter and Video Message to Stockholders Regarding Upcoming Special Meeting
Nov 3, 2021 08:06AM Advaxis (ADXS) Announces Leading Independent Proxy Advisory Firm ISS Recommends Advaxis Stockholders Vote “FOR” the Merger with Biosight
Nov 3, 2021 08:00AM Leading Independent Proxy Advisory Firm ISS Recommends Advaxis Stockholders Vote “FOR” the Merger with Biosight
Sep 10, 2021 08:30AM Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results and Provides a Business Update
Jul 14, 2021 04:01PM Advaxis to Present at the Non-Small Cell Lung Cancer Drug Development Summit
Jul 6, 2021 06:43AM Advaxis (ADXS) and Biosight Announce Entry into Definitive Merger Agreement
Jul 6, 2021 06:00AM Advaxis and Biosight Announce Entry into Definitive Merger Agreement
Jun 14, 2021 04:05PM Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update
May 19, 2021 05:01PM Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Apr 28, 2021 04:30PM Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Apr 10, 2021 08:31AM Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting
Mar 23, 2021 11:33AM Advaxis to Present Corporate Overview at the Benzinga Biotech Small Cap Conference
Mar 16, 2021 09:00AM Advaxis Reports First Quarter Ended January 31, 2021 Financial Results and Provides a Business Update
Mar 12, 2021 08:00AM Advaxis to Present at the American Association for Cancer Research (AACR) 2021 Annual Meeting
Jan 25, 2021 07:00AM Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update
Nov 9, 2020 08:01AM Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oct 26, 2020 08:06AM Advaxis' (ADXS) ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial
Oct 26, 2020 08:00AM Advaxis’ ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial
Oct 15, 2020 08:00AM Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020
Sep 24, 2020 08:02AM Advaxis (ADXS) Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer
Sep 24, 2020 08:00AM Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer
Sep 10, 2020 08:00AM Advaxis Reports Third Quarter Ended July 31, 2020 Financial Results and Provides a Business Update
Sep 4, 2020 04:30PM Advaxis (ADXS) Announces Resignation of CFO
Sep 4, 2020 04:30PM Advaxis Announces Resignation of Chief Financial Officer
Aug 27, 2020 08:00AM Advaxis to Present Corporate Overview at the LD Micro 500 Virtual Conference
Aug 3, 2020 08:04AM Advaxis (ADXS) Announces Common Stock Purchase Agreement for up to $20 Million with Lincoln Park Capital
Aug 3, 2020 08:00AM Advaxis Announces Common Stock Purchase Agreement for up to $20 Million with Lincoln Park Capital
Jun 23, 2020 08:00AM Advaxis to be Featured in “Grand Rounds: a Webinar in Biotech and Specialty Pharma,” Hosted by Alliance Global Partners
Jun 11, 2020 08:00AM Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update
Jun 1, 2020 08:00AM Advaxis to Host Second Quarter Financial Results and Business Update Conference Call on Thursday, June 11, 2020
May 14, 2020 08:00AM Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1/2 ADXS-503 Trial in NSCLC
Mar 13, 2020 09:00AM Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update
Mar 3, 2020 04:01PM Advaxis to Present at the 2020 LD Micro Virtual Conference
Feb 27, 2020 09:05AM Advaxis (ADXS) Reports Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC
Feb 27, 2020 09:00AM Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference
Feb 20, 2020 08:14AM Advaxis (ADXS) Reports Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC
Feb 20, 2020 08:00AM Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting
Feb 13, 2020 08:10AM Advaxis (ADXS) Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at ASCO
Feb 13, 2020 08:00AM Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium
Feb 11, 2020 01:00PM Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program
Feb 11, 2020 09:13AM Advaxis (ADXS) Gains 8% on Agreement with Personalis for ADXS-503 Trial
Feb 11, 2020 08:00AM Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program
Jan 30, 2020 09:23AM Data on Advaxis’ Clinical Programs to be Presented at Upcoming Medical Meetings
Jan 7, 2020 08:02AM Advaxis (ADXS) Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer
Jan 7, 2020 08:00AM Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer
Dec 20, 2019 08:00AM Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update
View More Recent Stories View Older Stories